U.S. Multiple Myeloma Mortality Rates Plummet Following Adoption of CAR T-Cell and Bispecific Therapies

U.S. mortality rates for multiple myeloma saw a record decline from 2021 to 2023. See how CAR T-cell and bispecific therapies are changing cancer outcomes.

By: AXL Media

Published: Apr 30, 2026, 5:19 AM EDT

Source: Information for this report was sourced from News-Medical.net and Oncotarget

Decades of Shifting Survival Trends

A major retrospective study led by the Mass General Cancer Center has identified a definitive turning point in the fight against multiple myeloma, a lethal cancer of the plasma cells. By analyzing nearly 50 years of data from the Surveillance, Epidemiology, and End Results (SEER) database, researchers documented a steady rise in mortality from 1975 through the mid-1990s. During this early period, clinical options were largely restricted to basic corticosteroids and alkylating agents, which offered limited long-term efficacy. The trend only began to reverse with the introduction of autologous stem cell transplantation, which provided the first evidence that modern clinical intervention could measurably extend the lives of patients at a population level.

The Rise of Targeted Mechanisms

The subsequent decline in mortality rates accelerated as the medical community moved away from broad-spectrum chemotherapy toward more precise targeted therapies. The development of immunomodulatory drugs and proteasome inhibitors introduced novel ways to combat the disease, such as enhancing cancer cell apoptosis and modulating the patient’s own immune response. According to lead author Navkirat Kahlon, these advancements did not just offer temporary remission but established a new standard for sustained disease control. This era marked the transition of multiple myeloma from a rapidly terminal diagnosis to a manageable, albeit complex, chronic condition for many American patients.

The Impact of Advanced Immunotherapies

The most significant finding in the report is the unprecedented drop in mortality recorded between 2021 and 2023. Researchers attribute this sharp decline to the clinical maturity of CAR T-cell therapies and bispecific antibodies. These high-tech treatments have demonstrated a unique ability to induce deep and durable responses, even in patients who had previously failed multiple lines of traditional therapy. The integration of monoclonal antibodies and maintenance strategies into standard care protocols has further solidified these gains, representing the most successful period of intervention in the history of the disease.